Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meg J Jardine

Showing results (1-10 of 125) with videos related to

Pageof 13
Sort By:
Diabetes, Obesity & Metabolism|April 8, 2025
A review of the safety of sodium-glucose co-transporter-2 inhibitorsDaniel Vincent O'Hara, Meg J Jardine
Kidney & Blood Pressure Research|December 3, 2020
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?Louisa Sukkar, Tamara Young, Meg J Jardine
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 1, 2020
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?Brendon L Neuen, Meg J Jardine, Vlado Perkovic
Therapeutic Advances in Chronic Disease|December 20, 2012
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trialsMin Jun, Jicheng Lv, Vlado Perkovic, et al.
Seminars in Dialysis|March 26, 2019
Cardiovascular adaptations associated with exercise in patients on hemodialysisMatthew P M Graham-Brown, Meg J Jardine, James O Burton
Diabetes, Obesity & Metabolism|April 9, 2020
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEYJinnie J Rhee, Meg J Jardine, Glenn M Chertow, et al.
Canadian Journal of Kidney Health and Disease|July 2, 2026
Barriers and Facilitators for Sodium-Glucose Cotransporter-2 Inhibitor Uptake and Implementation in Australia - Perspectives From Clinicians and Patients: An Interview StudyDaniel V O'Hara, Tae Won Yi, Meg J Jardine, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trialsAmanda Y Wang, Jessica N Ivany, Vlado Perkovic, et al.
Kidney Diseases (Basel, Switzerland)|April 13, 2026
Burden of Glomerular Diseases in Australia: A Data Linkage StudyNeeru Agarwal, Kristy P Robledo, Angus Ritchie, et al.
The Cochrane Database of Systematic Reviews|April 4, 2016
Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney diseaseYing Wang, Jessica N Ivany, Vlado Perkovic, et al.
Pageof 13

Showing results (1-10 of 125) with videos related to

Sort By:
Pageof 13
Diabetes, Obesity & Metabolism|April 8, 2025
A review of the safety of sodium-glucose co-transporter-2 inhibitorsDaniel Vincent O'Hara, Meg J Jardine
Kidney & Blood Pressure Research|December 3, 2020
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?Louisa Sukkar, Tamara Young, Meg J Jardine
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 1, 2020
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?Brendon L Neuen, Meg J Jardine, Vlado Perkovic
Therapeutic Advances in Chronic Disease|December 20, 2012
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trialsMin Jun, Jicheng Lv, Vlado Perkovic, et al.
Seminars in Dialysis|March 26, 2019
Cardiovascular adaptations associated with exercise in patients on hemodialysisMatthew P M Graham-Brown, Meg J Jardine, James O Burton
Diabetes, Obesity & Metabolism|April 9, 2020
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEYJinnie J Rhee, Meg J Jardine, Glenn M Chertow, et al.
Canadian Journal of Kidney Health and Disease|July 2, 2026
Barriers and Facilitators for Sodium-Glucose Cotransporter-2 Inhibitor Uptake and Implementation in Australia - Perspectives From Clinicians and Patients: An Interview StudyDaniel V O'Hara, Tae Won Yi, Meg J Jardine, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trialsAmanda Y Wang, Jessica N Ivany, Vlado Perkovic, et al.
Kidney Diseases (Basel, Switzerland)|April 13, 2026
Burden of Glomerular Diseases in Australia: A Data Linkage StudyNeeru Agarwal, Kristy P Robledo, Angus Ritchie, et al.
The Cochrane Database of Systematic Reviews|April 4, 2016
Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney diseaseYing Wang, Jessica N Ivany, Vlado Perkovic, et al.
Pageof 13